Thank you for your interest in ADCS legacy trials. All of the data sets below are available for sharing upon request. Please complete the Data Access and Sample Request form to request any of the data sets below. To download the request form, please click on the link or button found below and submit your completed form to: ADCSdataaccess@ucsd.edu.

Once your form is received, the ADCS Data and Sample Sharing Committee will review your request, and upon approval, a fully executed DUA (for data) and/or MTA (for samples) will be completed prior to data and sample sharing.

 

Please note that for recently completed trials, access to ADCS trial data remains restricted until the study’s primary manuscript has been published. Please also review the ADCS Data Access Policy and ADCS–Publication/Manuscript Citations Policy.

To request data sets, please complete the Data Access and Sample Request Form and it submit to ADCSdataaccess@ucsd.edu.

Protocol Number
Protocol Name
Study Duration
Treatment
Diagnostic Group(s)
Instruments/Biomarkers
Actual Baselined
Paper Publication Date
Data Portal Status
ADC-001Selegiline (SL)24 mosSelegiline or a-Tocopherol or Selegiline Placebo and a-tocopherol or Selegiline and a-tocopherol Placebo or PlaceboAD ADASCog, Blessed DRS, Blindness Eval, CDR, CERAD, ADL & Dependency Scale, Hackinski, MMSE, Modified UPDRS BL=341 04/1997
(Link to Pubmed)
Closed
ADC-002 New Instruments Trial (IN) 12 mos Non-Drug Study AD, NL ADL, CDR, CERAD, CGIC, CMAI, Hachinski, Executive Function, Facial Recognition, Letter Cancellation, Functional Assessment Staging, GDS, MMSE, Praxis, Severe Impair-ment Battery, Verbal Memory Immediate & Delayed Recall BL=306 06/1997
(Link to Pubmed)
Closed
ADC-002 New Instruments Trial (IN) (Spanish) 12 mos Non-Drug Study AD, NL ADL, CDR, CERAD, CGIC, CMAI, Hachinski, Executive Function, Facial Recognition, Letter Cancellation, Functional Assessment Staging, GDS, MMSE, Praxis, Severe Impair-ment Battery, Verbal Memory Immediate & Delayed Recall BL=94 06/1997
(Link to Pubmed)

Closed
ADC-003 Agitation (AP)24mos Haloperidol or Trazodone or Behavior Techniques or Placebo ADAPOE, Abnormal Involuntary Movement Scale, Blindness Eval, CGIC, CMAI, CERAD, CMAI, Hackinski, MMSE, Lawton and Brody ADL BL=149 11/2000
(Link to Pubmed)
Closed
ADC-005 Estrogen (ES)12mos + 3mos wash-outEstrogen (Premarin) or PlaceboADADASCog, ADASRECALL, ADAS RECOGNITION, APOE, Blindness Eval, BDRS, CDR, CSF, CGIC, Dependence Scale, Emotional Recognition, Hachinski, Hamilton, Lumbar Puncture, MAACL, MMSE, Newdot, QOL, Trailpeg, UPDRS BL=120 02/2000
(Link to Pubmed)
Closed
ADC-007 Melatonin (ML)8wks + 2wks placebo wash-outMelatonin or PlaceboADADASCog, ADAS RECOGNITION, ADASRL, ADL, APOE, Blindness Eval, COSTINF, EMOTION, Hamilton, Hachinski, MMSE, NPI, Parasomnia Questionnaire, QOL, Sleep Disorder Inv, UPDRS BL=15711/2003
(Link to Pubmed)
Closed
ADC-008 Mild Cognitive Impairment (MCI)36mos + 4mos donepezil visitsVitamin E or Donepezil HCL (Aricept) or Placebo MCIADACog, ADL, APOE/DNA Storage, Beck, Blindness Eval,MCI-CGIC, CDR, CT/MRI, GDS, Hamilton, Hachinski, Logical Memory I and II, MMSE, Neuropsychological Battery, Oxidative Biomarkers/DNA Storage, QOL, RUI BL=76906/2005
(Link to Pubmed)
Closed
ADC-010 Normal Control (NL)36mosNon-Drug StudyNLADACog, ADL, APOE/DNA Storage, Beck, Blindness Eval, Cleveland QOL, CGIC, CDR, GDS, Hamilton, Hachinski, Logical Memory I and II, MMSE, Neuropsychological Battery, QOL, RUITarget Enrollment=100PendingClosed
ADC-011 NSAIDS/Non-Steroidal (NS)12mos + 2mos wash-out Vioxx (Rofecoxib)25 mg or Alleve (Naproxen) 200 mg or Placebo ADADASCog, ADL, APOE/DNA, Blindness Eval, CDR, CT/MRI, Hachinski, MMSE, NPI, QOL, RUI BL=35106/2003
(Link to Pubmed)
Closed
ADC-012 Valproate (VP)6wks + 6wks open label Divalproex Sodium or PlaceboADBPRS, CMAI, Hachinski, MMSE BL=15311/2005
(Link to Pubmed)
Closed
ADC-014 TAP/DAP of Diffuse Lewy Body10wksQuetiapine(Seroquel) or Donepezil (Aricept) or Quetiapine and Donepezil or PlaceboAD, DLBADL, BPRS, CGIC, MMSE, NPI, R-MDS-D, UPDRS BL=4004/2007
(Link to Pubmed)
Closed
ADC-015 Simvastatin (LL)18mosSimvastatin or PlaceboADADASCog, APOE/DNA Storage, Blindness Eval ,CGIC, Dependency Scale, Hachinski, MMSE, NPI, QOL, RUI BL=40608/2011
(Link to Pubmed)
Closed
ADC-016 Homocysteine (HC) 18mosFolate, Vitamin B6, Vitamin B12 or Placebo ADADASCog, ADL, APOE/DNA Storage, Blindness Eval, CDR, CT/MRI, Hachinski, QOL, MMSE, NPI, RUI BL=40910/2008
(Link to Pubmed)
Closed
ADC-022 Valproate Neuroprotection (VN)24mos + 2mos wash-out Valproate or PlaceboADADL, ADASCog, APOE, CDR, CGIC, Biomarker, ClinEval, CDR, CMAI, CT/MRI, Family History, MMSE, NPI, QOL BL=31308/2011
(Link to Pubmed)
Closed
ADC-023 Huperzine (HU) 24wks + open label Phase I up to 48wks + open label Phase II up to 72 wks Huperzine A or PlaceboADADASCog, ADL, Blindness Eval, CGIC, CT/MRI, Hachinski, MMSE, NPI BL=21004/2011
(Link to Pubmed)
Closed
ADC-025 Antioxidant (AX)16wks + follow-up phone callVitamin E plus Vitamin C plus a-Lipoic Acid and Coenzyme Q, or PlaceboADADL, Biomarkes, BPRS, GDS, Hachinski, Lumbar Puncture, MMSE BL=7807/2012
(Link to Pubmed)
Closed
ADC-027 Docosahexaenoic Acid (DHA) 18mosDocosahexaenoic Acid or PlaceboADADAS-Cog, ADCS-ADL, APOE, CDR-SOB, FFQ, Hachinski, Lumbar puncture, MMSE, MRI, NPI, QOL BL=40211/2010
(Link to Pubmed)
Closed
ADC-030 Home-Based Assessment (HBA)1.9 - 4.1 yrsNon-Drug studyMCIAPO-E, DNA Banking, MMSE, MCI ADCS-ADL, Logical Memory Test, Boston Naming, Category Fluency, Digit Span, Trail Making Test (A & B), Digit Symbol Substitution, Immediate and Delayed Word Recall, East Boston Memory, Abbreviated TICS, QOL, Brief Cognitive Function Screening, Behavioral Scale, CGIC, Resource Use Inventory BL=42211/2018
(Link to Pubmed)
Closed
ADC-037Resveratrol (RES) 52wks500 mg resveratrol by once daily increasing at 13 week intervals to a maximum of 1,000 mg by mouth twice daily OR placeboMild-to-moderate ADADAS-Cog, CDR-SOB, ADCS-ADL, NPI, MMSE. Biomarkers include total Aβ, Aβ40, Aβ42, total and phosphorylated tau protein levels, rate of whole brain, hippocampal, and ventricular atrophy, as well as entorhinal cortex thickness change using volumetric magnetic resonance imaging (MRI) BL=11910/2015
(Link to Pubmed)
Closed